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“PREVALENCE OF HEPATOPULMONARY SYNDROME IN 
PATIENTS WITH CIRRHOSIS OF LIVER” 
 
ABSTRACT: 
INTRODUCTION: 
 Cirrhosis of liver is a very common disease which clinicians 
encounter both at primary and tertiary care. Development of pulmonary 
manifestations in cirrhosis has several clinical implications with regard to 
their management, since they carry a poor prognosis. These include 
pleural effusion, restrictive and obstructive lung disease, 
Hepatopulmonary syndrome and portopulmonary syndrome. 
Hepatopulmonary Syndrome (HPS) is a triad of liver disease, hypoxemia 
and intrapulmonary vascular dilatation. The reported prevalence of HPS 
in cirrhotic patients varies between 4% and 19%. 
 
AIMS & OBJECTIVES: 
 To study the pulmonary profile in patients with cirrhosis with 
reference to arterial hypoxemia. 
 To detect the presence of hepatopulmonary syndrome among 
cirrhotic patients. 
MATERIAL & METHODS: 
 Patients admitted in Institute of Internal Medicine, Madras Medical 
College and Rajiv Gandhi Government General Hospital, Chennai with 
cirrhosis of liver, proven by clinical, sonographic and endoscopy 
evidence, fulfilling the inclusion and exclusion criteria were included in 
the study. Data was collected in a pretested proforma meeting the 
objectives of the study.            
 40 cases were selected on the basis of the simple random sampling 
technique. Emphasis was placed on the pulmonary complaints and its 
impact. Patients were investigated for Arterial blood gas analysis, 
Spirometry and Contrast Echocardiogram. Relevant Statistical methods 
were applied. 
RESULTS:  
 In our study, Cirrhosis was common in young adults in the fourth 
decade with male to female ratio of 3:1. The most common respiratory 
system finding was right pleural effusion and it was the most common 
chest radiographic abnormality. Restriction was the most common 
abnormality in pulmonary function tests. Hypoxemia was present in 
17.5% of cirrhotics, out of which 4 patients (10%) were found to have 
Hepatopulmonary Syndrome (HPS). Orthodeoxia was the characteristic 
feature of the patients who had HPS. All 4 patients with HPS presented 
with cyanosis, orthodeoxia and spider naevi. Spider naevi could be a 
marker for the presence of intrapulmonary vascular dilatation. 
CONCLUSION  
 The feature of our study was the detection of hypoxemia in patients 
with cirrhosis of liver. Degree of hypoxemia worsens with higher grade 
of varices. Severity of liver disease also worsens hypoxemia. Hepato 
pulmonary syndrome was seen in 10% of patients with cirrhosis. The 
prevalence of HPS is influenced by the severity of liver disease. The only 
proven treatment for HPS is liver transplantation. As prognosis of HPS is 
poor, screening for its presence in cirrhotic patients is very important.  
KEYWORDS: Hepatopulmonary syndrome, Hypoxemia, Orthodeoxia, 
Contrast echocardiogram, arterial blood gas analysis. 
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INTRODUCTION 
 
Cirrhosis of liver is a very common disease which clinicians 
encounter both at primary and tertiary care. Cirrhosis is associated with 
several complications and overall carries a poor prognosis. The management 
of cirrhosis includes early detection and treatment of various complications 
like hepatic encephalopathy, coagulopathy, ascites, hepatorenal syndrome 
etc. Recently there has been an increased  interest  in   literature  about  
pulmonary  manifestations  of  cirrhosis  of  liver  which  are  equally   
important  and has  been  relegated  to  background  both  in  Indian  and  
western  countries. 
 
Development of pulmonary manifestations of cirrhosis has several 
clinical implications with regard to their management, since they carry a 
poor prognosis.  Cirrhosis and portal hypertension are associated with 
pulmonary manifestations that affect the pleura, lung parenchyma, and 
pulmonary vasculature. Dyspnea and hypoxemia are the predominant 
presentations.  
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The pulmonary disease manifestations include pleural effusion, 
obstructive lung disease, restrictive lung disease, impairments of pulmonary 
gas exchange (Hepatopulmonary syndrome) etc.,
1
  
Hepatopulmonary Syndrome (HPS) is a triad of 
1) Hypoxemia 
2) Pulmonary vascular dilatation 
3) Liver disease 
About 4% to 19% prevalence rate of HPS is observed in patients with 
cirrhosis.
2
 Most cases have occurred in patients with cirrhosis & portal 
hypertension. The prognosis of HPS is poor in cirrhosis.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
AIMS & OBJECTIVES 
 
 
 
 
 
 
 
 3 
 
AIM & OBJECTIVES 
 
 To study the pulmonary profile in patients with cirrhosis with 
reference to arterial hypoxemia. 
 
 To detect the presence of hepatopulmonary syndrome among 
cirrhotic patients. 
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 OF  
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REVIEW OF LITERATURE 
 
In 1884 Fluckiger described the death of a middle aged woman with 
digital clubbing & cyanosis who died as a consequence of syphilitic liver 
disease, esophageal bleeding, and hepatic coma.
3
 Postmortem examination 
showed abnormally dilated pulmonary vessels and thus led to the first 
description of a pulmonary manifestation of liver disease. 
In 1959, Rydell & Hoffbauer provided the first clinical and 
postmortem documentation of what was to be later called hepatopulmonary 
syndrome by Knudsen and Kennedy in 1977.
4
 The postmortem study 
showed both precapillary dilatation and direct AV communications 
following vascular injections with a solution of plastic vinyl acetate. In  
1994, however,  Krowka and Cortese  consolidated  the  definition of  HPS 
to be limited  to  an  arterial oxygen  tension  of less than 70 mmHg.
1 
 
CIRRHOSIS OF LIVER: 
 Cirrhosis of liver is a histopathologically described condition. It 
presents with various clinical features & complications. Cirrhosis is usually 
irreversible. But when the underlying cause is removed, fibrosis can be 
 5 
 
revered. This can be seen in chronic hepatitis C, hemochromatosis and 
alcohol liver disease.
5 
 
 In 1761, Gianbattista Morgagni, an anatomic pathologist, first 
identified the cirrhotic transformation of liver in his autopsy 
specimens.  
 In 1826, Laennec coined the term "cirrhosis" - meaning orange color 
in Greek, due to the yellowish-tan color of the cirrhotic liver.
6 
 
 In 1930, Roessle described pathogenesis of cirrhosis  parenchymal 
degeneration, regeneration and scarring. 
 
Cirrhosis is deﬁned by three morphological characteristics in the liver7 
1) Bridging fibrous septa 
2) Parenchymal nodules 
3) Architectural disruption of the liver 
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PATHOGENESIS OF CIRRHOSIS: 
Pathogenic processes include 
 Hepatocyte destruction,  
 Extracellular collagen deposition 
 Vascular reorganization 
 
Activation of stellate cells in liver 
 
Myofibroblast 
Transforming growth factor β 
Deposition of collagen (type I & III) in space of Disse 
 
Fibrosis  
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Figure1. Pathogenesis of cirrhosis 
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Figure 2: Cirrhosis of liver – gross pathology 
 
Figure 3: Cirrhosis of liver - Histology 
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CAUSES OF CIRRHOSIS:
5 
 
 10 
 
Prevalence of liver cirrhosis showed a marked geographic difference 
worldwide due to various etiology. Alcohol is the most common cause for 
liver cirrhosis. 
 
CLINICAL FEATURES OF CIRRHOSIS: 
 Fatigue 
 Anorexia 
 Weight loss 
 Jaundice 
 Digital Clubbing, hypertrophic osteoarthropathy 
 White nails10 
 Palmar erythema11 
 Spider naevi12 
 Gynaecomatia 
 Hypogonadism – testicular atrophy, loss of libido 
 Parotid enlargement – in alcoholics15 
 Dupuytren’s contracture13 
 Foetor hepaticus14 
 Ascites 
 11 
 
 Peripheral edema 
 Gastrointestinal bleeding 
 Sleep disturbances 
 Altered sensorium 
 Asterixis 
 Splenomegaly  
 
Figure 4: Palmar erythema 
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Figure 5: Clinical presentation of cirrhosis 
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LABORATORY FINDINGS IN CIRRHOSIS: 
 Liver enzymes:16 
o Moderate elevation of alanine aminotransferase (ALT)  & 
aspartate aminotransferase (AST)  
o Elevated alkaline phosphatase – more common in primary 
biliary cirrhosis & primary sclerosing cholangitis.  
o Elevated Gamma-glutamyl transpeptidase (GGT) – alcohol 
induced chronic liver disease.  
 Normal Bilirubin in well compensated cirrhosis. 
 Prolonged Prothrombin time 
 Decreased serum Albumin 
 Increased Globulins 
 Reversal of albumin-globulin ratio 
 Hyponatremia – correlates with disease severity 
 Hematologic17 
o Coagulopathy  
o Thrombocytopenia 
o Leukopenia 
o Anemia 
 14 
 
Ultrasonagraphy of abdomen:
18,19 
 Non-invasive test. 
 Small shrunken liver  
 Nodular surface 
 Increased liver echoes. 
Fibroscan – to assess the severity of liver fibrosis in cirrhosis.  
Liver biopsy 
20– the confirmatory test, sensitivity 80-100% 
 
PROGNOSTIC SCORES FOR CIRRHOSIS: 
 Child Turcotte Pugh classification (CPC) 
 Model for End stage Liver Disease (MELD) 
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Model for End stage Liver Disease SCORE 
 
Ranges between 6 and 40. 
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COMPLICATIONS OF CIRRHOSIS: 
1) Portal hypertension 
Gastro esophageal varices 
Portal hypertensive gastropathy 
Ascites 
Splenomegaly, Hypersplenism 
Spontaneous bacterial 
peritonitis 
2) Hepatorenal syndrome 
Type I 
Type II 
3) Hepatic encephalopathy 
4) Hepatopulmonary syndrome 
5) Portopulmonary syndrome 
6) Malnutrition  
7) Coagulopathy  
Factor deficiency 
Fibrinolysis 
Thrombocytopenia 
8) Bone disease 
Osteopenia 
Osteomalacia 
Osteoporosis 
9) Haematological abnormalities 
Anemia 
Neutropenia 
Thrombocytopenia 
Hemolysis  
 
PORTAL HYPERTENSION: 
Hepatic venous pressure gradient (HVPG) >5 mm Hg  indicates portal 
hypertension.
8
  
 17 
 
 
It is caused by 
 Increased intrahepatic resistance to blood flow. 
 Increased splanchnic blood flow. 
Figure 6: Pathogenesis of Portal hypertension 
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CLASSIFICATION OF PORTAL HYPERTENSION: 
 
 
 19 
 
 
 
Clinical features: 
 Upper gastrointestinal bleeding due to varices,  
 Ascites & peripheral edema 
 Splenomegaly 
 Reduced platelets and leukocytes.  
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Treatment: 
Aimed at 
 Reducing portal blood flow 
 Decreasing intrahepatic resistance 
Drugs decreasing Portal venous blood flow:     
 Nonselective β-blockers – propranolol, nadolol 
 Vasopressin 
 Somatostatin & octreotide 
Drugs reducing Intrahepatic Resistance:     
 α1-Adrenergic blockers – prazosin 
 Angiotensin receptor blockers (ARBs) – losartan 
 Nitrates 
Endoscopic therapy for varices. 
Shunt procedures – TIPS  
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Figure 7: Anatomy of portal circulation 
 
 
VARICEAL HEMORRHAGE: 
 Bleeding from varices occurs due to increased portal pressure. It is 
dreadful complication.  
 22 
 
Increased portal pressure  portosystemic collaterals  dilate varices, walls 
become thinner.  
Any further increase in variceal pressure / size  rupture & clinical 
hemorrhage 
Gastroesophageal varices – most common source of upper gastrointestinal 
bleed in cirrhotic patients.  
Incidence 5–15% / per year.5 
Bleeding from varices occurs in one third of cirrhotics 
Caput medusa – prominent veins radiating from umblicus 
Sites of portal-systemic anastomosis in cirrhosis: 
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Figure 8: Sites of portal-systemic anastomosis in cirrhosis
21 
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Endoscopy 
Varices are identified by endoscopy. 
 Upper GI endoscopy  gastroesophageal varices  
 Sigmoidoscopy  rectal varices 
Varices are graded by endoscopy in to 3 types 
 Grade I 
 Grade II 
 Grade III 
Figure 9: Endoscopic Grading of varices 
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Figure 10: Upper GI endoscopy showing esophageal varices 
 
Portal hypertensive gastropathy – in fundus of stomach, mosaic-like pattern 
 
Factors predicting the risk of bleeding:
5 
 Severity of cirrhosis (Child's class, MELD score) 
 Height of hepatic vein wedge vein pressure 
 Location & size of varices 
 Endoscopic findings – cherry red spots, red wale signs, erythema  
 
Treatment of variceal hemorrhage due to portal hypertension include  
 Acute variceal hemorrhage – resuscitation, vasoconstricting agents 
like somatostatin or octreotide, emergency endoscopic sclerotherapy 
or band ligation 
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 Primary prophylaxis – non selective beta blockers or endoscopic 
variceal band ligation 
 Prevention of re-bleeding after an initial variceal bleed – beta 
blockade, portosystemic shunt surgery (TIPS)  
 
ASCITES: 
Ascites - accumulation of free fluid in the peritoneal cavity.  
Portal hypertension is the common cause for ascites.  
Malignant or infectious causes can be present as well. 
Pathogenesis:
5 
 Increase in portal pressure & vasodilation of the splanchnic arterial 
system  increase in portal venous inflow & increased production of 
splanchnic lymph. Vasodilating factors (nitric oxide) are responsible 
for vasodilatory effects. 
 Activation of renin-angiotensin-aldosterone system and 
hyperaldosteronism leads to retension of sodium causing fluid 
accumulation & expansion of ECF volume. This results in peripheral 
edema and ascites 
 27 
 
 
 
 Hypoalbuminemia (due to reduced synthesis from liver) & reduced 
plasma oncotic pressure  fluid loss from vascular compartment into 
peritoneal cavity. 
 Ascites develops insidiously. Patients usually have 1-2 litres of fluid 
in the abdomen before they are aware that there is an increase.  
 Massive ascites  compromise respiratory function, dyspnoea occurs.  
 Hepatic hydrothorax also contributes to respiratory symptoms.  It is 
common on right side. Free flow of fluid into the thoracic cavity 
occurs through a diaphragmatic rent. 
 28 
 
SBP – SPONTANEOUS BACTERIAL PERITONITIS 
 Spontaneous infection of ascitic fluid without intraabdominal source.  
 Occur in up to 30% of individuals 
 25% in-hospitality mortality rate.  
 Most common organisms – Escherichia coli & other gut bacteria.  
 Diagnosis criteria - ascitic fluid absolute neutrophil count >250 
cells/µL. 
 
HEPATORENAL SYNDROME (HRS): 
Functional renal failure with no obvious renal pathology.  
Incidence 10% in advanced cirrhosis / acute liver failure.  
 Type I HRS – progressive impairment in kidney function with 
significant reduction in creatinine clearance within 1-2 weeks.  
 Type II HRS – reduction in GFR with an elevation of serum creatinine 
level, but it is fairly stable, better outcome than type I HRS. 
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HEPATIC ENCHEPHALOPATHY: 
Hepatic encephalopathy (HE) – transient & reversible neurologic & 
psychiatric manifestations in the setting of heaptic failure.
22
  
Occurs in 50-70% of cirrhotics 
Poor prognostic indicator  
Without liver transplantation in HE – survival rates 42% & 23% respectively 
in 1
st
 and 3
rd
 year 
Symptoms - mild mental disturbances to coma.  
Triggered by a precipitating event resulting in raised level of ammonia.  
Precipitating events 
 Infections 
 Increased protein load 
 Gastrointestinal bleeding 
 Electrolyte disturbances - hypokalemia 
Intra & extrahepatic shunting of portal blood into systemic circulation  
toxic substances not detoxified by liver  metabolic abnormalities in the 
central nervous system. 
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Treatment:  
Avoiding precipitating events 
Reduction of elevated serum ammonia production 
Disaccharides (non absorbable) – lactulose 
L-ornithine L-aspartate, Zinc, Flumazenil 
Transplantation of liver 
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COAGULOPATHY: 
Coagulopathy common in cirrhotic patients.  
Decreased clotting factor synthesis.  
Impaired clearance of anticoagulants.  
Hypersplenism due to portal hypetension  Thrombocytopenia 
 
CARDIOVASCULAR CHANGES IN CIRRHOSIS: 
Hyperdynamic circulation occurs in cirrhosis  
Decreased peripheral vascular resistance, decreased arterial BP and 
increased cardiac output.  
Kowalski et al
23
 were the first to report that cirrhotic patients had abnormal 
cardiovascular changes and a prolonged QTc.  
Cirrhotic cardiomyopathy is characterized by  
 Systolic dysfunction 
o Resting ejection fraction <55% 
o With exercise, volume change or pharmacological stress  
blunted increase in cardiac output 
 32 
 
 Diastolic dysfunction 
o E/A ratio < 1.0 
o Prolonged isovolumetric relaxation time & deceleration time 
 Electrophysiological changes 
Mechanism of cirrhotic caridiomyopathy 
 
 33 
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PULMONARY MANIFESTATIONS IN CIRRHOSIS 
Pulmonary complications of Cirrhosis can affect the lung 
parenchyma, pulmonary circulation and the pleura. Pulmonary 
manifestations in cirrhosis can present as follows,  
 Hepato-pulmonary syndrome (HPS) 
 Hepatic hydrothorax 
 Porto-pulmonary hypertension (PPH)  
The most common clinical features are Dyspnea and hypoxemia. 
 
HEPATOPULMONARY SYNDROME: 
Hepatopulmonary Syndrome (HPS) is characterized by
23 
 Liver diasease 
 Hypoxemia   
 Pulmonary microvascular dilatation 
Liver-lung relationship was first noted in 1884 by Fluckiger.
3
 But this 
was not formalized at that time. In 1997 Kennedy & Knudson explained 
HPS as a disease presenting with hypoxemia and intrapulmonary vascular 
dilatations.
4
  
 35 
 
About 4% to 19% prevalence rate of HPS.
2
 Most cases have occurred 
in patients with cirrhosis & portal hypertension. Due to different cut-off 
values (in various studies) for defining arterial hypoxemia there is disparity 
in the prevalence rate of HPS.  
 
PATHOPHYSIOLOGY: 
Pathological hallmark – dilatation of pulmonary microvasculature.  
Pulmonary microvascular dilatation 
 
Ventilation-perfusion mismatching 
 
Anatomical & functional shunt physiology 
 
Hypoxemia 
Functional vasodilatation was due to reduced synthesis or inadequate 
metabolism of vasoactive agents. 
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Nitric oxide (NO) is the leading vasoactive agent. There is increased 
production nitric oxide from the pulmonary circulation. In cirrhotic patients 
with HPS, there is increase in exhaled NO.
25
 Both endothelial & inducible 
NO synthases are overexpressed in pulmonary microcirculation. N 
G
-nitro -L 
arginine methyl ester (L-NAME) and Methlyene blue inhibit NO production 
which transiently alleviates HPS 
 37 
 
In the normal vasculature, endothelin-1 (ET-1), produced locally in 
endothelial cells, acts as a paracrine vasoconstrictor through activation of the 
endothelin A (ET) receptor on smooth muscle cells. To a lesser extent, 
luminal release of ET-1 stimulates nitric oxide (NO) production by 
endothelial nitric oxide synthase (eNOS) through activation of the 
endothelin B (ET A) receptor on endothelial cells.
26
  
In HPS, ET-1 reaches the lung through the pulmonary circulation and 
acts as an endocrine vasodilator by stimulating the ET receptor on the 
luminal surface of the endothelial cell and preferentially increasing NO 
production. This is depicted in the following diagram 
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Figure 11: Effect of Endothelin-1 in the normal and HPS pulmonary 
microvasculature
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Figure 12: Hypothesis in intrapulmonary dilatation in hepatopulmonary 
syndrome 
 
MECHANISM OF HYPOXEMIA:
83 
 Abnormal Diffusion 
 Ventilation perfusion (V/Q) mismatch 
 40 
 
Significant improvement in arterial oxygenation is observed in 
patients of HPS who are given 100% oxygen.
27
 This supports the finding 
that the VA/Q mismatch is a predominant cause of hypoxemia in HPS.
28 
Hypoxemia is also caused by a ‘‘diffusion-perfusion defect’’.29 
Pulmonary blood flow is increased to such an extent in patients with liver 
disease that there is insufficient time for adequate exchange of oxygen at the 
capillary–alveolar interface. 
In support of this theory, investigators have found a correlation 
between impairments in oxygenation and the transit time for blood flow 
through   pulmonary circulation in patients who have liver disease but who 
do not have hypoxemia.
24 
Figure 13: Pathophysiology of hypoxemia in HPS 
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 Arterial oxygenation is influenced by position in all patients, but this 
effect is accentuated in patients who have HPS.
30
 Under normal 
circumstances arterial oxygenation falls in the supine position. It is due to 
gravity which pushes the abdominal contents into the diaphragm, reducing 
functional residual capacity and causes venous admixture as a result of 
impaired VA/Q mismatching.
31,84
 Oxygen desaturation in the supine position 
is often enhanced in patients who have liver disease. This is because of the 
added effects of ascites and increased intrathoracic blood volume on 
functional residual capacity. 
In contrast, patients with HPS often experience orthodeoxia and 
platypnea, deoxygenation and dyspnea in standing & sitting positions when 
compared to supine position.
 
These are due to redirection of pulmonary 
blood flow in upright posture, to dilated vessels in lung bases.
32 
Orthodeoxia is a unique observation that can be used to confirm a 
diagnosis of HPS.
1 
A fall in oxygen saturation upon assuming the standing 
position has been observed in patients who have mild liver disease who do 
not suffer from oxygen desaturation
 
and therefore do not have HPS.
33
 The 
latter observation indicates that the diagnostic and prognostic value of 
orthodeoxia is an independent observation that needs further clarification. 
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In normal lung  oxygen diffuses rapidly into the capillary (8-15 µm)  
In anatomical shunt, blood bypasses the alveolus.  
In HPS  oxygen unable to diffuse into the center of dilated capillary (15-
100 µm)  hypoxia occurs. 
Figure 14: Intrapulmonary dilatation in HPS 
 
 
CLINICAL FEATURES: 
The clinical course of HPS is poorly defined. Acute development 
(days to weeks) of the syndrome appears unlikely. High suspicion is needed 
to diagnosis HPS. Clinical features of HPS include  
 43 
 
 Dyspnoea – insidious onset, most common feature34 
 Platypnoea 
 Orthodeoxia  
 Cyanosis 
 Digital Clubbing 
 Spider angioma82 
     Figure 15:Spider naevi 
 
Progressive worsening of hypoxemia over months to years has been 
reported with an approximate mortality of 41% 2.5 years from diagnosis.
38
 
Comorbid conditions (infection/sepsis) can result in acute and dramatic 
respiratory deterioration. 
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Orthodeoxia:
35,86 
 Accentuation of hypoxemia in upright position compared to supine 
position 
 Fall in PaO2  ≥5%  
 Fall in PaO2  ≥4 mm Hg  
 Mechanism – In upright posture  more perfusion in lung bases  
greater functional shunting 
 Highly specific for HPS.  
 
Alizadeh et al (2006)
36
 conducted a study in which  
 Dyspnea - presenting feature in HPS 
 Cyanosis - seen in 90% of cases.  
 
Significant relationship exist between spider angioma and 
vasodilatation of pulmonary bed.
37
 Hence spider nevi can be a cutaneous 
marker in patients with intrapulmonary dilatations. 
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DISEASE SEVERITY: 
HPS can be graded according to the degree of hypoxemia 
 
DIAGNOSIS OF HPS: 
HPS can be diagnosed by 
 Arterial blood gas analysis 
 Echocardiography with contrast 
 Lung perfusion scanning 
 CT pulmonary angiography 
 High resolution CT 
2D transthoracic contrast echocardiogram:
85 
The most sensitive & most common technique employed 
Saline is used as contrast agent – produces microbubbles on echo 
Positive test – visualization of microbubbles in left cardiac chambers after 3 
cardiac cycles
39,40 
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Figure 16: Contrast echocardiogram to detect intrapulmonary 
vasodilatation 
 
Echocardiogram before contrast.  
 
Echo after saline contrast: Right atrium and Right ventricle showing 
microbubbles   
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Positive contrast test in HPS: Visualization of microbubbles in left atrium 
(arrow) and left ventricle (3 cardiac cycles later) 
 
Echocardiogram can also assess  
 Cardiac dysfunction 
 Pulmonary arterial pressure – pulmonary hypertension 
Contrast echo more sensitive than lung perfusion scan
78 
Lung perfusion scanning: 
 Radionucleotide used – Technetium-99m-labelled macro aggregated  
albumin  particles  (
99m 
TcMAA scan) 
 Macro aggregated albumin particles (50-100 micrometer) – injected 
IV. 
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 Normally all particles are trapped within the pulmonary vasculature. 
 In HPS patients, some particles pass through dilated pulmonary 
capillaries and lodge in various systemic arterial bed. 
 Shunt fraction calculated from quantitative imaging of lung & brain.41 
 Shunt  fraction  > 6%  significant 
Advantage: Specific  for  detection  of   HPS  even  in  the presence of  co-
existing  intrinsic  pulmonary  disease 
Lung perfusion scanning less sensitive than contrast echo.
42 
Figure 17: Lung perfusion scan in HPS: radionucleotide detected in kidneys 
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Pulmonary angiography: 
Two angiographic patterns are seen
43 
 
 
High resolution CT: 
Detect dilated pulmonary vessels
44 
Degree of dilatation observed can be correlated with the severity of gas 
exchange   
 
SCREENING OF HPS: 
Screening for HPS is important especially in patients awaiting liver 
transplantation. Screening tests include 
 Pulse oximetry 
 Arterial blood gas analysis 
 Contrast echocardiogram 
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 Detect intrinsic cardio-pulmonay disease 
Screening for HPS 
 
 
NATURAL HISTORY AND PROGNOSIS:
45 
 Mortality  is  significant  in  patients  with HPS  and  may  be  in  part 
due to  causes  directly  related  to intra  pulmonary  vasodilatation.  
  The prognosis of HPS is poor in cirrhosis. 
 HPS is a significant risk factor for patient’s survival.  
 Hepatopulmonary syndrome can occur in mild liver disease also.  
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 HPS is associated with increased mortality and morbidity in patients 
awaiting liver transplantation. 
 Degree of arterial hypoxemia influence patient’s survival. This was 
shown in a study conducted by Swanson and colleagues in 2005 in 
which survival is worse in patient group with decreased PaO2. 
 Causes of death – secondary to complications of liver dysfunction & 
portal hypertension, correlates with degree of hypoxemia. 
 
MANAGEMENT OF HPS: 
Medical treatment: 
Following drugs were tried in HPS 
 Garlic preparations80  
 Pentoxifylline49,50 – TNF alpha inhibitor 
 Methylene blue53,87 & inhaled N (G)-nitro-L-arginine methyl ester54 – 
direct inhibition of nitric oxide  
 Somatostatin 
 Indomethacin79 
 Steroids 
 N-acetylcysteine   
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 Almitrine bimesylate51,52 
 Oxygen therapy 
 Iloprost56 
Intervention Radiological therapy: 
 Transjugular intrahepatic portosystemic shunt (TIPS)46,47,48 – control 
portal pressure 
 Embolotherapy88,89 with Yttrium-90 glass microspheres55  – eliminate 
intrapulmonary shunts 
Liver transplantation:
90 
 Only proven treatment for HPS.  
 After liver transplantation complete resolution of hypoxemia occurs in 
85% of patients.
57
  
 In some patients resolution may take more time58 (more than a year). 
 Mortality after liver transplantation is significantly high with 1-year 
survival rate – 71%.59  
 Severe degree of hypoxemia & prominent intrapulmonary shunting  
associated with increased mortality rate. 
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Complications after OLT:  
 Pulmonary arterial hypertension60 
 Cerebral embolic hemorrhage61 
 Post-operative hypoxemia requiring prolonged  ventilation62 
Indication for orthotopic liver transplantation in HPS:
81 
 If PaO2   50 – 60 mmHg   
 If PaO2   <50 mmHg (on an individual basis) 
Liver transplantation is the ideal treatment for HPS as there are no proven 
medical therapy. 
 
HEPATIC HYDROTHORAX  
Presence of pleural effusion without intrinsic respiratory or cardiac 
pathology in patients with cirrhosis.  
Incidence up to 10%
63
   
Movement of free fluid from peritoneal cavity in to pleural cavity through 
small diaphragmatic rents. 
Can occur even without ascites.  
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Most common on right side
63
 (67%)
 
May be bilateral (17%) or left sided 17%  
Spontaneous bacterial empyema can occur
64
   
Treatment: 
 To decrease ascitic fluid formation 
 Therapeutic aspiration (to relieve dyspnea)  
 To obliterate the rent between pleura & peritoneum 
 Shunt surgery (TIPS) 
 Pleurodesis  
Figure 18: Chest X-ray showing right pleural effusion in a cirrhotic 
patient 
(A) CXA – PA VIEW                                                                          
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(B) CXR – RIGHT LATERAL VIEW 
                           
 
 
PORTOPULMONARY HYPERTENSION: (PPH) 
Portopulmonary hypertension (PPH) is characterized by
65 
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Severity of PPH: 
 
Incidence of PPH in cirrhosis - 6% 
 
PATHOGENESIS:
92,93 
Pathogenesis of PPH is not well understood 
Embolic factors:  
 Embolic material  via portosystemic shunts  enter lungs 
Plexogenic factors:
66,67
  
 Bypassed vasoactive substances 
 Produce plexogenic arteriopathy 
 Increased pulmonary blood flow & proliferation of smooth muscle  
endothelial damage and vascular remodeling 
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Risk of developing pulmonary hypertension – increases with duration of 
portal hypertension 
Figure 19: Histology of lung in portopulmonary hypertension 
 
Intimal and medial thickening of pulmonary artery (straight arrow) 
Channel like structures forming plexiform lesions (curved arrow) 
 
CLINICAL FEATURES  
 Asymptomatic in most patients 
 Exertional dyspnea  dyspnea at rest 
 Fatigue  
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 Syncope 
 Chest pain 
 Elevated JVP 
 Loud pulmonary component (P2) of  2nd heart sound 
 Systolic murmur 
 Severe pulmonary hypertension68 
 
DIAGNOSIS  
 Electrocardiogram 
 Right atrial enlargement 
 Right ventricular hypertrophy  
 Right bundle branch pattern. 
 Chest X-Ray 
 Pulmonary arteries – prominent  
 Cardiomegaly 
 Computed Tomography:69 
 Evidence of pulmonary hypertension – main pulmonary artery 
diameter ≥29 mm 
 Echocardiogram 
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 Noninvasive screening test 
 Elevated right ventricular systolic pressure (RVSP) 
 Tricuspid regurgitant jet  Pulmonary hypertension91 
 Right heart catheterization94 
 Confirmation of PPH  
 Measures pulmonary artery pressure 
 
PROGNOSIS: 
Mean survival – 15 months 
High perioperative mortality
68 
Screening for portopulmonay hypertension – mandatory in patients awaiting 
liver transplantation 
 
TREATMENT OF PORTOPULMONARY HYPERTENSION:  
 Vasodilators - mainstay of therapy, reverses the vasoconstriction   
 Prostacyclin95 – epoprostenol70,71,72, iloprost  vasodilator & platelet  
aggregation  inhibitor  
 Endothelin receptor antagonists – Bosentan73,74, Ambrisentan   
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 Inhaled  Nitric Oxide 
 Phosphodiesterase  inhibitors75 
 L-arginine  
 Diuretics 
Liver transplantation: 
Role of OLT (orthotopic liver transplantation) – controversial 
Not the curative treatment in PPH 
Contraindicated in patients with mean PAP > 50 mm Hg 
Liver Transplantation – indicated in selected patients76 after clinical 
improvement by medical therapy 
Medical therapy – used to bridge PPH patients to OLT77 
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MATERIALS AND METHODS 
SOURCE OF DATA: 
 Patients admitted in Institute of Internal Medicine, Madras Medical 
College and Rajiv Gandhi Government General Hospital, Chennai-3 
diagnosed to have Cirrhosis of liver, fulfilling the inclusion and exclusion 
criteria were included in the study group. 40 such patients were taken up for 
this study. 
 
STUDY DESIGN:  
A hospital based observational study 
 
STUDY DURATION:  
6 months: March 2014-August 2014 
 
INCLUSION CRITERIA: 
 Proven cases of cirrhosis of liver by clinical, endoscopic and 
sonographic evidence. 
 62 
 
EXCLUSION CRITERIA: 
 Patients with coexisting primary pulmonary diseases like COPD, 
Bronchial asthma, ILD etc.  
 Coexisting intrinsic heart disease.  
 Patients with life threatening complications of cirrhosis like active 
upper gastrointestinal haemorrhage, hepatic encephalopathy.  
 Smokers. 
 
DATA COLLECTION AND METHODS: 
Data was collected in a pretested proforma from eligible patients. 40 
patients were selected on the basis of simple random sampling. They were 
subjected to detailed history taking and clinical examination. The following 
investigations were done. 
 Complete blood count 
 LFT 
 RFT with electrolytes 
 Chest X-ray 
 Electrocardiogram 
 Viral markers 
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 USG of abdomen,  
 Upper gastrointestinal endoscopy, 
 Arterial blood gas analysis  
 Pulmonary function test 
 Contrast Echocardiogram 
 
ABG: 
Arterial blood gas analysis was done by a single radial puncture under 
local  anaesthesia, while the patient was in the supine position breathing 
room air and the sampling was repeated with the patients standing ,breathing 
100% oxygen. Each of these positions was maintained for a minimum of 10 
min. 
The presence of hypoxemia and orthodeoxia was also detected. 
Orthodeoxia is defined as fall in PaO2 levels more than 3mmHg on changing 
position from supine to standing and hypoxemia if PaO2 is less than 
70mmHg in any position at rest. Alveolar Arterial gradient of partial 
pressure of oxygen was taken as elevated if it were elevated more than 
30mmHg (calculated as P (A-a) O2=PaO2-150-1.25xPaCO2). 
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PFT – Pulmonary function test: 
All patients were subjected to PFT using spirometer in the standing 
position according to standard procedures.  
 Forced expiratory volume in one second (FEV1),  
 Forced vital capacity (FVC),  
 Peek Expiratory Flow Rate (PEFR) 
Predicted values for each of the parameters were obtained from 
standardized references. 
 
Echocardiogram: 
A 2-D transthoracic contrast enhanced echocardiography was done for 
all patients.  Contrast-enhanced echocardiography with agitated saline was 
done to detect pulmonary vascular dilatation. 10ml of agitated solution of 
normal saline was administered to all the patients in the supine position. A 
positive test was defined as any visualization of microbubbles in the left 
heart chambers after three cardiac cycles after its appearance in the right 
ventricle in any of three injections 
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Figure 20: Contrast echocardiogram showing intrapulmonary shunting 
 
 
Hepatopulmonary syndrome in cirrhosis identified by 
 Delayed positive contrast echocardiography  
o microbubble visualization in left atrium occurring  within 3 to 6 
beats after its visualization on right side 
 Abnormal oxygenation  
o PaO2 <70mmHg or  
o P(A-a)O2 >20mmHg in any position (supine, standing) 
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STASTICAL METHODS APPLIED: 
Datas were analysed using the SPSS software. Statistical significance 
was indicated by the Chisquare test. Variables were considered to be 
significant if p<0.05 
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OBSERVATION AND RESULTS 
Table 1. AGE DISTRIBUTION 
Age group (years) Frequency Percent 
 
20 -30 6 15.0 
31-40 13 32.5 
41-50 10 25.0 
51- 60 9 22.5 
>60 2 5.0 
Total 40 100.0 
 
Most cases of cirrhosis (13 patients) occur in the age group of 31-40 
(32.5%) years 
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Table 2. SEX DISTRIBUTION 
 
 Frequency Percent 
 
MALE 31 77.5 
FEMALE 9 22.5 
Total 40 100.0 
 
 
 
 
Among 40 patients included in our study, 31patients (78%) were males and 
9 patients (22%) were females 
 
78% 
22% 
SEX DISTRIBUTION 
MALE
FEMALE
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Table 3. ETIOLOGY OF CIRRHOSIS 
Etiology Frequency Percent 
Alcohol  24 60.0 
Hepatitis B virus 3 7.5 
Hepatitis C virus 2 5.0 
Others  11 27.5 
Total  40 100 
 
 
 In our study, the most common cause for cirrhosis in the study group 
was alcohol seen in 24 patients (60%).  
 
 
Alcohol 
60% 
Hepatitis B 
7% 
Hepatitis C 
5% 
Others 
28% 
ETIOLOGY OF CIRRHOSIS 
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DISTRIBUTION OF PRESENTING COMPLAINTS AMONG CASES 
 
 In our study, abdominal distension was the most common presenting 
symptom present in 30 patients (75%). The most common respiratory 
symptom was cough present in 10 patients (25%) followed by breathlessness 
in 7 patients (17.5%) 
 
  
 
 
0 5 10 15 20 25 30
Abdominal distension
Yellowish discolouration of eyes
Cough
Breathlessness
Easy fatiguablity
Fever
Swelling of Legs
Frequency 
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Table 4. DISTRIBUTION OF CLUBBING 
 
 Frequency Percent 
 
NO 27 67.5 
YES 13 32.5 
Total 40 100.0 
 
 
 
 
 Among 40 cirrhotic patients, clubbing was seen in 13 patients (32%)  
68% 
32% 
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DISTRIBUTION OF  CLUBBING 
NO
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Table 5. DISTRIBUTION OF CYANOSIS 
 Frequency Percent 
 
NO 36 90.0 
YES 4 10.0 
Total 40 100.0 
 
 
 
 
 
 Out of the 40 cirrhotic patients, cyanosis was seen in 4 patients (10%) 
 
 
 
 
90% 
10% 
DISTRIBUTION OF CYANOSIS 
NO
YES
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Table 6. DISTRIBUTION OF SPIDER NAEVI 
 Frequency Percent 
 
PRESENT  8 20.0 
ABSENT 32 80.0 
Total 40 100.0 
 
 
 
 
 In our study of 40 patients, spider naevi was seen in 8 patients (20%) 
 
 
20% 
80% 
DISTRIBUTION OF SPIDER NAEVI 
Present
Absent
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Table 7. RESPIRATORY SYSTEM FINDINGS 
 Frequency Percent 
 
Pleural 
effusion 
10 25 
Normal  30 75 
   
Total 40 100.0 
 
 
 
 
In our study, respiratory system examination showed pleural effusion 
in 10 patients (25%) which is the most common pulmonary finding in 
patients with cirrhosis of liver. 
Pleural effusion, 
25% 
Normal, 75% 
RESPIRATORY SYSTEM FINDINGS 
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Table 8. CHEST X-RAY FINDINGS 
 Frequency Percent 
 
BPE 2 5.0 
CM 3 7.5 
LPE 1 2.5 
N 27 67.5 
RPE 7 17.5 
Total 40 100.0 
BPE – bilateral pleural effusion, CM – cardiomegaly, LPE – left pleural effusion, RPE – 
right pleural effusion, N – normal x-ray 
 
 In our study right sided pleural effusion was seen in 7 patients 
(17.5%), left sided pleural effusion was seen in 1 patient (2.5%), bilateral 
pleural effusion was seen in 2 patients (5%), cardiomegaly was seen in 3 
patients (7.5%) and normal chest x-ray was seen 27 patients (67.5%) 
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BPE – bilateral pleural effusion, CM – cardiomegaly, LEFT PE – left pleural effusion, 
RIGHT PE – right pleural effusion 
 
In chest x-ray, right pleural effusion was more common, followed by 
cardiomegaly and bilateral pleural effusion. Left pleural effusion was less 
commonly seen  
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Table 9. UPPER GI ENDOSCOPY FINDINGS 
Esophageal 
varices (EV) 
Frequency Percent 
 
Grade 1 17 42.5 
Grade 2 16 40.0 
Grade 3 7 17.5 
Total 40 100.0 
 
 
 
 
 In our study, 17 patients (42.5%) showed Grade 1 varices, 16 patients 
(40%) showed Grade 2 varices and 7 patients (17.5%) showed Grade 3 
varices.   
Grade 1, 43% 
Grade 2, 40% 
Grade 3, 17% 
UPPER GI ENDOSCOPY FINDINGS 
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Table 10. DISTRIBUTION OF PFT PATTERN 
  
 Frequency Percent 
 
Normal 29 72.5 
Restrictive 11 27.5 
Total 40 100.0 
 
 
 
 
 
  In our study, 29 patients (72.5%) showed normal pulmonary function 
tests by spirometry whereas 11 patients (27.5%) showed restrictive pattern 
of lung disease.  
73% 
27% 
PULMONARY FUNCTION TEST PATTERN 
Normal PFT
Restrictive
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Table 11. DISTRIBUTION OF ASCITES 
 
 Frequency Percent 
 
NO 10 25.0 
YES 30 75.0 
Total 40 100.0 
 
 
 
 
 
 In our study, ascites was seen in 30 patients (75%) whereas ascites 
was absent in 11 patients (25%) 
25% 
75% 
DISTRIBUTION OF ASCITES 
NO
YES
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Table 12. DISTRIBUTION OF SPLENOMEGALY 
 Frequency Percent 
 
NO 2 5.0 
YES 38 95.0 
Total 40 100.0 
 
 
 
 
 In our study of 40 patients, splenomegaly was predominantly present 
in 38 patients (95%) 
  
5% 
95% 
DISTRIBUTION OF SPLENOMEGALY 
NO
YES
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Table 13. CVS FINDINGS 
 Frequency Percent 
 
ESM 11 27.5 
Normal 29 72.5 
Total 40 100.0 
 
 
 
 In our study, cardiovascular system examination was normal in 29 
patients (72.5%) whereas Ejection systolic murmur (ESM) was present in 11 
patients (27.5%)   
27% 
73% 
CVS FINDINGS 
Ejection Systolic Murmur
Normal
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Table 14. DISTRIBUTION OF HYPOXIA AMONG CASES  
 Frequency Percent 
 
PRESENT 
(PaO2 <70) 
7 17.5 
ABSENT 33 82.5 
Total 40 100.0 
 
 
 
 
 In our study of 40 cirhhotic patients, hypoxia (PaO2 <70 mm Hg) was 
present in 7 patients (17.5%) 
 
 
18% 
82% 
DISTRIBUTION OF  HYPOXIA 
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ABSENT
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Table 15. CHILD PUGH CLASS 
CPC class Frequency Percent 
 
A 8 20.0 
B 20 50.0 
C 12 30.0 
Total 40 100.0 
 
 
 
 In our study of 40 cirrhotic patients, 8 patients (20%) were in Child-
Pugh class A, 20 patients (50%) were in Child-Pugh class B and 12 patients 
(30%) were in Child-Pugh class C 
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Table 16. CONTRAST ECHOCARDIOGRAM FINDINGS 
 Frequency Percent 
 
IPS 4 10.0 
N 36 90.0 
Total 40 100.0 
IPS – intrapulmonary shunting, N – normal study 
 
 
 In our study, 4 patients (10%) showed intrapulmonary shunting in 
contrast echocardiogram 
 
 
 
10% 
90% 
CONTRAST ECHO FINDINGS 
IPS
NORMAL
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Table17.  PREVALENCE OF HEPATOPULMONARY SYNDROME 
AMONG CIRRHOTICS 
Hepatopulmonary 
syndrome 
(Hypoxia + IPS) 
Frequency  Percent  
Present  4 10 
Absent  36 90 
Total 40 100 
 
 
In our study of 40 cirrhotic patients, hepatopulmonary syndrome was 
present in 4 patients (10%) 
 
Absent 
90% 
Present 
10% 
Prevalence of HPS 
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Table 18. CORRELATION BETWEEN GRADING OF VARICES 
AND PaO2 & FEV1 
 G
ra
d
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g
 o
f 
v
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es
 
 
    
C
O
R
R
E
L
A
T
IO
N
 
P
 V
A
L
U
E
 
Mean SD Minimum Maximum Range 
PaO2 1 77.94 3.83 72.00 82.00 10.00 -0.43 0.01 
2 76.69 7.17 64.00 86.00 22.00 
3 74.57 12.30 60.00 90.00 30.00 
FEV1 1 88.21 6.69 76.00 98.20 22.20 -0.19 0.23 
2 82.68 13.25 54.00 98.20 44.20 
3 83.64 10.45 70.10 96.20 26.10 
 
 
 
 
 
 
 
 88 
 
 
Figure 21. CORRELATION BETWEEN GRADING OF VARICES & 
PaO2 
 
 
 In our study, PaO2 was compared with the grading of varices. It was 
found that there was a decrease in PaO2 with severity of varices which was 
statistically significant with p-value 0.01 
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Figure 22: CORRELATION BETWEEN GRADING OF VARICES & 
FEV1 
 
 
 
In our study, FEV1 was compared with the grading of varices. It was 
found that there was no significant correlation between FEV1 and grading of 
varices. 
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Table 19. CORRELATION BETWEEN PaO2 & SEVERITY 
OF LIVER DISEASE (CHILD PUGH CLASS) 
  
  
Child Pugh class (CPC) 
Total 
C
O
R
R
E
L
A
T
IO
N
 
P
 V
A
L
U
E
 
A B C 
PaO2 HYPOXIA Count 0 2 5 7 
-0.41 0.01 
NORMAL Count 8 18 7 33 
Total Count 8 20 12 40 
 
 
 
 
 
 
 
 
 
 
 
 91 
 
CORRELATION BETWEEN PaO2 & SEVERITY OF LIVER 
DISEASE (CHILD PUGH CLASS) 
 
 
 
In our study, PaO2 was correlated with the severity of liver disease 
(by Child-Pugh class). It was found that there was a decrease in PaO2 with 
severity of liver disease which was statistically significant with p-value 0.01 
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Table 20. CORRELATION BETWEEN FEV1 & SEVERITY OF 
LIVER DISEASE (CHILD-PUGH CLASS) 
 
 
      
  
C
O
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R
E
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A
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IO
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P VALUE 
 C
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d
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ss
 
 
    
Mean SD Minimum Maximum Range 
FEV1 A 90.0125 12.13736 62.10 98.20 36.10 -0.17 0.30 
B 83.7900 10.80691 54.00 96.20 42.20 
C 84.3333 8.50030 72.50 96.00 23.50 
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Figure 23: CORRELATION BETWEEN FEV1 & SEVERITY OF 
LIVER DISEASE (CHILD-PUGH CLASS) 
 
In our study, FEV1 was correlated with the severity of liver disease 
(by Child-Pugh class). It was found that there was no significant correlation 
between FEV1 and severity of liver disease 
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Table 21. CORRELATION BETWEEN PFT & SEVERITY OF LIVER 
DISEASE (CHILD-PUGH CLASS) 
   
 
Child Pugh class 
 
 
PFT Pattern Total   
N R Chi 
square P value 
 
A 
Count 7 1 8   
    4.514 0.105 
B 
Count 16 4 20 
      
C 
Count 6 6 12 
      
 
Total  
 
 29 11 40 
 
 In our study, PFT was correlated with the severity of liver disease 
among the study group. No significant correlation was obtained from our 
study and it is not statistically significant. 
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CORRELATION BETWEEN PFT & SEVERITY OF LIVER 
DISEASE (CHILD-PUGH CLASS) 
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Table 22. CORRELATION BETWEEN 
CHILD-PUGH CLASS & HPS 
  
  
 HPS Total   
YES NO Chi square p value 
Child Pugh 
class 
A 
Count 0 8 8   
      
B 
Count 0 20 20 10.370 0.006 
      
C 
Count 4 8 12   
      
Total 
 4 36 40   
      
 
 
In our study, prevalence of HPS was correlated with the severity of 
liver disease (by Child-Pugh class). All the 4 patients with HPS were under 
Child-Pugh class C. This indicates that the prevalence of HPS increases with 
increasing severity of liver disease. This was statistically significant in our 
study with p-value 0.006 
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DISCUSSION 
          Our study was conducted in patients with cirrhosis of liver to know 
the prevalence of hepato-pulmonary syndrome. Our study population 
included 40 patients who were diagnosed as cirrhosis of liver either by 
clinical, endoscopic or sonographic evidence. All 40 patients were evaluated 
for presence of hypoxemia and were screened for the presence of hepato-
pulmonary syndrome. Analysis was made to study the correlation between 
hypoxemia & severity of liver disease, hypoxemia & grading of varices, and 
to establish the correlation between severity of liver disease and prevalence 
of hepato-pulmonary syndrome using Chi-square test. Following were the 
observations made from our study in cirrhotic patients. 
Age distribution: 
Out of 40 patients, majority of cases were in the age group of 31-40 
years (32.5%). This showed that cirrhosis is most commonly seen in young 
adults. 
Sex distribution  
Out of 40 patients in this study, 31 patients (77.5%) were males and 9 
patients (22.5%) were females. Male to female ratio is 3:1.  
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Etiology  
Among 40 patients, Alcohol was the most common etiology in 24 
patients (60%) followed by other causes of cirrhosis in 11 patients (27.5%). 
This can be compared to studies of De BK et al.,
 95
 Rao MY et al.
 96
        
 
Presenting complaint  
Among the presenting complaints, abdominal distension was most 
common symptom present in 30 patients (75%). 
The most common respiratory symptom was cough present in 10 
patients (25%) followed by breathlessness in 7 patients (17.5%)    
 
Clinical signs:  
Out of 40 patients studied, 38 patients (95%) had Splenomegaly, 30 
patients (75%) had ascites. Clubbing was present in 13 patients (32.5%), 
cyanosis in 4 patients (10%) and spider naevi in 8 patients (20%). 
Splenomegaly was the significant finding in patients of cirrhosis and it 
indicates the presence of portal hypertension.  
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Child-Pugh class: 
 In our study, out of 40 patients, 20 patients (50%) were in class B, 12 
patients (30%) were in class C and 8 patients (20%) were in class A. 
Majority of patients were in class B. Child-Pugh class is a good indicator of 
the severity of liver disease. It is used to assess the patients for liver 
transplantation 
 
Respiratory system examination findings  
In respiratory system pleural effusion was the commonest 
examination finding present in 10 patients (25%). Right sided pleural 
effusion was more common. This was similar to study conducted by Hourani 
et al.
97
  
 
Chest X ray findings  
      The most common radiographic finding was Right sided pleural effusion 
seen in 7 patients (17.5%) followed by bilateral pleural effusion in 2 patients 
(5%) and left sided pleural effusion in 1 patient (2.5%). This finding was 
similar to that seen in the study of Hourani et al.
97
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Endoscopic findings  
The most common endoscopic finding was Grade 1 varices present in 
17 patients (42.5%) followed by Grade 2 varices in 16 patients (40%) and 
Grade 3 varices in 7 patients (17.5%) 
 
Hypoxemia  
Out of 40 patient, 7 patients (17.5%) showed hypoxemia with PaO2 
<70 mm Hg which was comparable to a study of Lange  P A et al.
98
   
        Clinical signs of hypoxemia like cyanosis was present in 4 patients 
(10%), orthodeoxia in 4 patients (10%) which were similar to the finding 
observed by Krowka et al.
38 
The correlation between partial pressure of oxygen (PaO2) and 
grading of oesophageal varices was done in this study. It was observed that 
there was a decrease in PaO2 with higher grade of varices. This was 
statistically significant with p-value of 0.01. It was similar to the 
observations in the study of Zhang HY et al and Schenk P et al 
 The correlation between PaO2 and severity of liver disease was also 
done. It was observed that there is progressive decrease in PaO2 with 
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increasing severity of liver disease. This was statistically significant in our 
study. PaO2 was more decreased in patients with Child-Pugh class C than 
other classes. 
 
Pulmonary function tests  
 In pulmonary function tests, a restrictive pattern was the most 
common abnormality present in 11 patients (27.5%). A restrictive pattern of 
PFT could be observed in 25% of cases while 3.4% cases have an 
obstructive pattern. The above observation in our study was similar to the 
study of Rao MY et al.
96
   
  The correlation between predicted values of Forced Expired Volume 
in One Second (FEV1) with grading of varices as well as with the severity of 
liver disease was done in this study. It was observed that no significant 
correlation exists between predicted values of FEV1 and grading of varices 
& severity of liver disease. 
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HPS – Hepatopulmonary syndrome  
Out of 40 patients in our study, HPS was identified in 4 patients 
(10%). All 4 patients had hypoxemia (PaO2 <70 mm Hg) and intra 
pulmonary shunting as established by contrast echo.  They all had varices 
indicating portal hypertension. Hence increased portal venous pressure is a 
significant factor for development of HPS. The prevalence of HPS in 
cirrhotics in this study was comparable to studies conducted by Schenk P et 
al.,
2
 Krowka et al.,
38 
De BK et al.,
95
 Rao MY et al.,
96
  and Hourani et al.
97
  
            Orthodeoxia was present in all 4 patients who had HPS. All 4 
patients of HPS had spider angiomas. This can be compared with other 
studies including De BK et al.,
95
 Hourani et al.,
97
 and  Krowka et al.
38 
 
 In this study correlation between prevalence of HPS and severity of 
liver disease was done. It was observed that prevalence of HPS was 
increased with the increasing severity of liver disease. All 4 patients of HPS 
in this study were under Child-Pugh class C. 
 
 
 
  
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
Following results were concluded from our study: 
 Cirrhosis of liver was more commonly seen in middle aged adults (in 
4
th
 decade) and is common in males than females with male to female 
ratio of 3:1 
 The most common pulmonary complaint was cough followed by 
breathlessness. Pleural effusion was the most common respiratory 
system finding observed.  
 The most common chest radiographic abnormality was the right sided 
pleural effusion followed by cardiomegaly and bilateral pleural 
effusion.   
 Restrictive pattern of lung disease was the most common abnormality 
detected by pulmonary function tests in cirrhosis  
 Grade 1 varices was the most common endoscopic finding. 
 Majority of patients were in the Child-Pugh class B. 
 Significant correlation was observed between PaO2 and grading of 
varices. Pao2 was found to be decreased with higher grade of varices. 
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 Significant correlation was observed between PaO2 and severity of 
liver disease (Child-Pugh class). Pao2 was found to be decreased with 
increasing severity of liver disease. Hypoxemia was more common in 
class C followed by class B 
 Hepatopulmonary syndrome (HPS) was the important complication 
present in patients with hypoxemia. All patients with hypoxemia had 
portal hypertension. It is a significant factor for development of 
hypoxemia.  
 Cyanosis, orthodeoxia and spider naevi were observed in all patients 
of HPS 
 HPS was most commonly seen in patients with Child-Pugh Class C. 
 There was a significant correlation between the prevalence of HPS 
among cirrotics and the severity of liver disease.  
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SUMMARY 
 Development of pulmonary manifestations of cirrhosis has several 
clinical implications with regard to their management, since they carry a 
poor prognosis. 
 Diagnosis of HPS needs a high index of suspicion among cirrhotics. 
As the prognosis of HPS poor, all patients with cirrhosis of liver must be 
screened for the presence of hypoxemia and HPS. The only proven treatment 
for HPS is liver transplantation.   
 All patients with HPS showed hypoxemia and intrapulmonary 
shunting on contrast echocardiogram. The clinical markers of hypoxemia 
such as cyanosis, orthodeoxia were seen in all patients of HPS. All the 
patients with HPS had esophageal varices indicating the presence of portal 
hypertension. Elevated portal pressure probably is a significant factor for the 
development of HPS.  
 Hypoxemia worsens with higher grade of varices and increasing 
severity of liver disease. Significant correlation exists between HPS 
prevalence and severity of liver disease. HPS is commonly underdiagnosed. 
Screening for HPS is important in patients with cirrhosis of liver.   
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ANNEXURES 
 
 
 
 
 
 
 
  
“PREVALENCE OF HEPATOPULMONARY SYNDROME IN 
PATIENTS WITH CIRRHOSIS OF LIVER” 
 
PROFORMA 
 
NAME:      AGE/SEX: 
 
ADDRESS:      OCCUPATION: 
 
PRESENTING COMPLAINTS: 
 Abdominal distension 
 Yellowish discolouration of eyes 
 Swelling of legs 
 Breathlessness 
 Easy fatiguablity 
 Cough with expectoration 
 Others  
 
PAST HISTORY: 
 Ischemic heart disease 
 Hypertension 
 Diabetes 
 Pulmonary TB 
 Bronchial asthma 
 Blood transfusion 
 Jaundice 
 
PERSONAL HISTORY: 
 Smoking 
 Alcohol 
 
GENERAL EXAMINATION: 
 Built      
 Nourishment  
 Height 
 Weight  
  
 Pallor 
 Icterus  
 Clubbing 
 Cyanosis  
 Pedal edema 
 Lymphadenopathy 
 Jugular venous pulse 
 Signs of Liver cell failure 
 
VITAL SIGNS: 
 
 PR- 
 BP- 
 RR- 
 
SYSTEMIC EXAMINATION: 
 
 PER ABDOMEN: 
 
 CARDIOVASCULAR SYSTEM: 
 
 RESPIRATORY SYSTEM: 
 
 CENTRAL NERVOUS SYSTEM: 
 
INVESTIGATIONS: 
 
 Complete hemogram 
 Liver function tests 
 Renal function tests 
 USG abdomen 
 Chest X-ray 
 ECG 
 Echocardiogram 
 Viral markers 
 Arterial blood gas analysis 
 Pulmonary function tests 
  
INFORMATION SHEET 
We are conducting a study on “PREVALENCE OF 
HEPATOPULMONARY SYNDROME IN PATIENTS WITH 
CIRRHOSIS OF LIVER” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your specimen may be 
valuable to us. 
            
The purpose of this study is to assess the pulmonary manifestations in 
patients with cirrhosis with the following factors Age, Sex, Presenting 
Complaints, Etiology of cirrhosis, Clinical findings, Chest X ray findings, 
Endoscopy findings, Arterial blood gas analysis, Pulmonary function test, 
Echocardiographic findings.  
 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do certain tests which in any way do not affect 
your final report or management. 
 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation resulting 
from the research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal which may 
aid in the management or treatment. 
 
 
 
Signature of Investigator    Signature of Participant 
 
Date : 
Place : 
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1 25 M 25736 + - - + - - + - PLE N + + 9.2 2.1 2.4 16.5/1.4 Neg RPE EV G3 B 86 40 96 89.3 87.2 96 N N 
2 36 M 27206 + + - + - - - - N N - + 10.2 4.3 3.1 12.9/1.2 Neg N EV G2 B 84 42 98 54 49.2 40.8 R N 
3 56 M 28299 - + - - - - - - N N - + 9.6 4.4 2.6 15.4/1.4 Neg N EV G1 B 72 32 90 78.2 80.1 80 N N 
4 35 M 28429 + + + - - - + - PLE ESM + + 6.5 3.2 2.8 14.4/1.4 Neg RPE EV G1 B 82 36 96 90 96 97 N N 
5 40 F 31034 - + - - - - + - N N + + 8.9 2.8 3.0 18.6/1.7 Neg N EV G1 B 81 35 88 76 80.2 82 N N 
6 51 M 33519 + + + + - - - + N N + + 8 3.9 3.2 15.4/1.5 Neg N EV G2 C 86 40 92 90 86.4 86 R N 
7 45 M 36045 + + - - - - + - PLE N + + 10.6 2.5 3.1 13.3/1.0 Neg RPE EV G2 B 78 41 91 96 90.2 86 N N 
8 26 M 36113 + - - - - - - - N N - + 11.2 1.2 3.4 16.5/1.5 Neg N EV G2 A 81 41 90 98 90.1 98 N N 
9 43 F 38378 - + + - - - + - N ESM + + 6.7 2.2 2.5 14.4/1.3 HBV CM EV G1 B 77 36 88 84.2 82.6 80.1 N N 
10 55 M 40375 + + - + + + + + N N + + 9 3.4 2.1 16.4/1.4 Neg N EV G3 C 60 34 84 72.5 68.1 76.2 R IPS 
11 40 M 40545 - - - - - - - - N N - + 10.4 1.4 3.5 17.6/1.6 Neg N EV G2 A 72 40 90 90 92.3 95.1 N N 
12 54 M 40513 + + - - - - + - PLE N + + 11 4.6 2.0 18.1/1.8 Neg RPE EV G2 C 81 42 91 96 96 95 N N 
13 60 M 45739 + + - + + + + + N N + + 9.5 6.5 2.9 19.9/2.1 Neg N EV G2 C 68 35 82 76.2 74 80 R IPS 
14 44 M 47099 - - - - - - - - N N - - 10.2 1.3 3.0 15.7/1.4 Neg N EV G1 A 80 42 96 86.2 84.2 90 N N 
15 30 F 48193 - - + + - - + - N ESM + + 7.2 1.2 3.2 16.6/1.6 Neg N EV G2 A 86 45 96 62.1 60 76.2 R N 
16 27 M 48390 + + - - - - + + PLE N + + 9.8 3.2 2.4 15.6/1.4 Neg RPE EV G2 C 76 38 96 88.2 90.2 92.2 N N 
17 42 M 48192 + + - - - - - - N N + + 10.4 4.1 2.8 14.9/1.4 Neg N EV G1 B 72 36 90 80.2 82.2 96.2 N N 
18 40 F 51171 - - + - - - + - PLE ESM + + 7 2.0 3.0 16.3/1.5 HBV BPE EV G1 B 81 41 92 88.2 90.2 92.2 N N 
19 35 M 53683 + + - - - - + - PLE N + + 9.8 3.1 2.6 16.3/1.5 Neg LPE EV G1 C 82 42 93 90.2 92.2 86.2 N N 
20 35 F 53651 + + + - - - + - N ESM + + 6.6 2.8 3.2 14.5/1.3 Neg CM EV G1 C 81 36 93 92.2 94.6 96.2 N N 
21 40 M 53608 - + - - - - + - PLE N + + 10.2 3.2 3.0 13/0.9 HCV RPE EV G1 B 77 41 96 96.2 98.2 98 N N 
22 65 F 56309 + + - + - - - - N N - + 10 4.1 2.8 15.2/1.4 Neg N EV G2 B 78 39 94 68.5 56 50.8 R N 
23 52 M 56561 - + - + + + + + N N + + 10.5 5.2 2.1 19.6/2.0 Neg N EV G3 C 63 35 86 76 70.5 77.2 R IPS 
24 46 M 58972 - + - - - - + - N N + + 11 3.2 2.7 14.3/1.2 Neg N EV G1 B 72 35 88 80.7 80.6 78.1 N N 
25 38 M 59051 + + - - - - + - N N + + 10.2 4.1 3.0 15.1/1.3 Neg N EV G2 B 78 36 90 89.2 90.2 90.1 N N 
26 34 M 61760 + + - + - - - - N N - + 11.4 3.0 2.2 15.3/1.4 Neg N EV G1 C 72 37 91 90.2 91.2 90.4 N N 
27 48 F 64300 - - + - - - - - N ESM - + 7 1.2 3.0 16.8/1.5 Neg N EV G3 A 80 36 90 91.2 86.2 90.1 N N 
28 50 F 64210 + + + - - - + - PLE ESM + + 5.6 3.1 2.4 14.7/1.3 Neg BPE EV G1 B 77 41 94 96.2 98.2 96 N N 
29 55 M 64404 + + - - - - + - N N + + 10 2.1 2.6 13.1/1.2 Neg N EV G1 B 82 40 99 90.2 90.2 90.5 N N 
30 26 M 64392 - + - + - - - + N N + + 9.2 4.2 3.0 14.6/1.3 HCV N EV G2 C 66 35 81 74.1 72.2 76 R N 
31 42 F 67062 - - + - - - + - N ESM + + 6.3 1.6 2.2 15.1/1.3 Neg N EV G1 B 81 41 96 86.2 90.8 98 N N 
32 40 M 72070 + + - + + + + + N N + + 9.6 4.8 3.1 16.9/1.6 Neg N EV G2 C 64 32 84 76.2 76 62 R IPS 
33 70 M 74812 + + + - - - + - N ESM + + 5.2 2.2 2.6 16.1/1.4 Neg N EV G3 B 80 42 96 96.2 98.2 98 N N 
34 36 M 75498 + + - - - - - - N N - + 9.2 2.6 2.8 17.8/1.4 Neg N EV G1 A 78 43 96 96.2 97.0 96 N N 
35 55 M 76549 + + - - - - + + PLE N + + 9.5 3.8 2.6 16.4/1.3 Neg RPE EV G3 C 90 39 96 90.2 86.1 90.2 N N 
36 51 M 77233 - + + + - - - - N ESM - + 6.3 4.2 3.0 13.4/1.2 Neg CM EV G2 B 68 34 78 80 76 68 R N 
37 29 M 77274 + + - - - - - - N N + + 10.2 3.4 2.8 14.6/1.4 Neg N EV G2 B 84 40 90 86.2 84.2 86 N N 
38 45 M 77292 - + - + - - - - N N + + 9.8 2.8 3.2 16.2/1.5 Neg N EV G3 B 63 33 81 70.1 70 68 R N 
39 37 M 80033 - + + - - - + - N ESM + + 6 2.1 2.9 15.1/1.4 HBV N EV G2 A 77 45 90 98.2 98.2 95 N N 
40 45 M 80073 + - - - - - + - N N + - 9.6 1.5 3.0 13.4/1.2 Neg N EV G1 A 78 44 96 98.2 98 94 N N 
 
CVS-cardiovascular system, PLE-pleural effusion, ESM-ejection systolic murmur, HBV-hepatitis B virus, HCV-hepatitis C virus, Neg-negaitve,  
RPE-right pleural effusion, LPE-left pleural effusion,BPE-bilateral pleural effusion, CM-cardiomegaly, EVG-esophageal varices grading, N-normal,  
R-restrictive lung disease, IPS-intrapulmonary shunting 
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